In line with this notion, CD73 expression is a biomarker of poor prognosis in breast cancer (109) and the use of chitosan-lactate nanoparticles to target CD73-specific small interfering RNA (siRNA) in combination with a DC vaccine have been successfully tested in breast cancer models after inhibiting tumor growth, and MDSCs (64). This evidence concerns the gene NT5E and neoplasm.